Floatz logo

Ineo-Vac-R01

Pancreatic Cancer Resectable

Zhejiang UniversityvaccinePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

10 Active assets in the Pancreatic Cancer Resectable cohort.

Asset / SponsorPhaseRating
Huaier Granule
Xi'an Jiaotong University
Phase 4B
Surufatinib
Sun Yat-sen University
Phase 2CCC
Acetylsalicylic Acid
German Cancer Research Center
Phase 2CCC
Avelumab
Nathan Bahary, MD
Phase 2CCC
Individualized Anti-Tumor New Antigen Ineo-Vac-R01
Zhejiang University
Phase 1/2CC

View all 11 →

Same molecule, other indications

Ineo-Vac-R01 is also rated in:

Advanced Hepatocellular Carcinoma (HCC)Dormant
CC
Indicative ·
45 / 100
View asset →
Pancreatic Cancer MetastaticDormant
CC
Indicative ·
45 / 100
View asset →
hepatocellular carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →